Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06885853
Recruiting Observational

Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

NCT06885853 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2025-05-07
Last updated
2025-05-15

Condition(s) studied

Monkeypox

Study summary

This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men aged over 18 years * Have received two doses of MVA-BN vaccine as an initial schedule * Eligible for a booster dose of MVA-BN (according to the HAS recommendation) * Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment * Covered by social security (excluding AME) Exclusion Criteria: * History of mpox (virologically confirmed) * Be under guardianship or curatorship * Be subject to a judicial protection measure * Have a contraindication to vaccination against mpox

Primary outcome measure(s)

  • Immunogenicity a of a booster dose of MVA-BN vaccine — 12 months
    To evaluate the immunogenicity at 12 months of a booster dose of MVA-BN vaccine administered subcutaneously in HIV PrEP users.

Trial sites (1)

FacilityCityRegionStatus
CIC 1417Cochin-Pasteur Paris Paris Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Fusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions Active, not recruiting
neonAtal motoR paTtErn autoMatIc analySis Recruiting
Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis Recruiting
Effect of Adding Vasopressin on Cardiac Output, Blood Pressure, Diuresis, and Tissue Perfusion Indices in Patients With Septic Shock Starting soon
Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06885853 on ClinicalTrials.gov ↗ ← All trials in France